Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍영미 | * |
dc.contributor.author | 김관창 | * |
dc.date.accessioned | 2019-10-08T16:30:09Z | - |
dc.date.available | 2019-10-08T16:30:09Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 1738-5520 | * |
dc.identifier.issn | 1738-5555 | * |
dc.identifier.other | OAK-25419 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251616 | - |
dc.description.abstract | Background and Objectives: Elevated endothelin (ET)-1 level is strongly correlated with the pathogenesis of pulmonary arterial hypertension (PAH). Expression level of nicotinamide adenine dinucleotide phosphate oxidase (NOX) 4 is increased in the PAH patients. Ambrisentan, a selective endothelin receptor A (ERA) antagonist, is widely used in PAH therapy. The current study was undertaken to evaluate the effects of ambrisentan treatment in the monocrotaline (MCT)-induced PAH rat model. Methods: Rats were categorized into control group (C), monocrotaline group (M) and ambrisentan group (Am). The M and Am were subcutaneously injected 60 mg/kg MCT at day 0, and in Am, ambrisentan was orally administered the day after MCI injection for 4 weeks. The right ventricle (RV) pressure was measured and pathological changes of the lung tissues were observed by Victoria blue staining. Protein expressions of ET-1, ERA, endothelial nitric oxide synthase (eNOS) and NOX4 were confirmed by western blot analysis. Results: Ambrisentan treatment resulted in a recovery of the body weight and RV/left ventricle+septum at week 4. The RV pressure was lowered at weeks 2 and 4 after ambrisentan administration. Medial wall thickening of pulmonary arterioles and the number of intra-acinar arteries were also attenuated by ambrisentan at week 4. Protein expression levels of ET-1 and eNOS were recovered at weeks 2 and 4, and ERA levels recovered at week 4. Conclusions: Ambrisentan administration resulted in the recovery of ET-1, ERA and eNOS protein expression levels in the PAH model. However, the expression level of NOX4 remained unaffected after ambrisentan treatment. | * |
dc.language | English | * |
dc.publisher | KOREAN SOC CARDIOLOGY | * |
dc.subject | Hypertension | * |
dc.subject | pulmonary | * |
dc.subject | Endothelin receptor antagonists | * |
dc.subject | Monocrotaline | * |
dc.subject | Gene expression | * |
dc.title | Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model | * |
dc.type | Article | * |
dc.relation.issue | 9 | * |
dc.relation.volume | 49 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 866 | * |
dc.relation.lastpage | 876 | * |
dc.relation.journaltitle | KOREAN CIRCULATION JOURNAL | * |
dc.identifier.doi | 10.4070/kcj.2019.0006 | * |
dc.identifier.wosid | WOS:000483593700011 | * |
dc.author.google | Lee, Hyeryon | * |
dc.author.google | Yeom, Arim | * |
dc.author.google | Kim, Kwan Chang | * |
dc.author.google | Hong, Young Mi | * |
dc.contributor.scopusid | 홍영미(35210025100;55841904000;56063366100) | * |
dc.contributor.scopusid | 김관창(36652690000) | * |
dc.date.modifydate | 20240415130647 | * |